Raya Therapeutic, Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on December 4, 2025 - 11:15 GMT

Raya Therapeutic unveils its Raya CARES pipeline of five clinical-stage compounds

Each new chemical entity (NCE) has substantial clinical safety data and a unique mechanism of action to treat ALS, PD, and other neurodegenerative diseases. MONTREAL, QUEBEC, CANADA, December 4, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on September 2, 2025 - 16:33 GMT

Raya Therapeutic Announces Selection of one of its 5 compounds onto the EXPERTS-ALS Clinical Platform Trial

Positive data from this clinical study could lead to a registration trial of the compound for the treatment of ALS/MND. MONTREAL, QUEBEC, CANADA, September 2, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) a mission-driven company focused on …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on June 3, 2025 - 06:00 GMT

Raya Therapeutic Announces Two Posters at the ENCALS Meeting in Turin, Italy June 3-6

Kim Staats, PhD., to present results of preclinical studies with RT1978 (Epertinib) and the combination of 2 NCEs with distinct mechanisms (RT1972 & RT1999). MONTREAL, QUEBEC, CANADA, June 3, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc. (“Raya …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on May 8, 2025 - 10:00 GMT

Raya Therapeutic Appoints Juan Carlos Gomez MD, MBA, Chief Medical Officer of Shionogi and Company to its Board

Dr. Gomez brings extensive neuroscience and orphan disease development experience to Raya as it plans multiple clinical trials in 2026. MONTREAL, QUEBEC, CANADA, May 8, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) a mission-driven company …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on March 3, 2025 - 18:00 GMT

Raya Therapeutic Announces FDA and EMA Orphan Drug Designations for ALS with RT1978 (epertinib)

The orphan drug designations (ODDs) are from both the FDA & EMA and for the treatment of Amyotrophic Lateral Sclerosis (ALS). MONTREAL, QUEBEC, CANADA, March 3, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) a mission-driven company …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on January 9, 2025 - 16:00 GMT

Raya Therapeutic Announces 9 Orphan Drug Designations Across its 5 Clinical Stage Compounds

The orphan drug designations (ODDs) are from both the FDA & EMA and for the treatment of Amyotrophic Lateral Sclerosis (ALS) & other neurodegenerative diseases. MONTREAL, QUEBEC, CANADA, January 9, 2025 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on December 5, 2024 - 15:00 GMT

Raya Therapeutic Announces Oral Presentation and Poster at International Symposium on ALS/MND in Montreal December 6-8

Dr. Paul Lingor to present Phase 2 ROCK-ALS study. Raya also presenting promising new preclinical data of a combination of two new chemical entities (NCEs). MONTREAL, QUEBEC, CANADA, December 5, 2024 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya”) …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on October 17, 2024 - 12:31 GMT

Raya Therapeutic Announces Publication in The Lancet Neurology of ROCK-ALS Study Data for Fasudil in ALS

Phase 2 trial showed Fasudil is safe and tolerable and provided evidence to support further investigation as a potential disease-modifying treatment for ALS. MONTREAL, QUEBEC, CANADA, October 17, 2024 /⁨EINPresswire.com⁩/ -- Raya Therapeutic Inc., (“Raya …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...